Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chile reviews AUGE coverage upgrade:

This article was originally published in Clinica

Executive Summary

In the month to August 1, Chile's AUGE (universal healthcare access with explicit guarantees) programme provided care to almost 27,000 patients of cases involving the 16 conditions that gained coverage on July 1, taking the total to 56 (see Clinica No 1264, p 3). The vast majority of cases, just over 20,000, were for emergency dental surgery; of the remainder, almost 1,100 were for hearing aids; others included cataract and gastric surgery. All but 283 patients (those covered by private contribution schemes, ISAPREs) were covered by the national health insurance fund, Fonasa. AUGE is cofinanced by the state and the private health insurance sector.

You may also be interested in...



Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel